白蛋白结合型紫杉醇治疗转移性乳腺癌的临床疗效与安全性观察  

Clinical Efficacy and Safety of Abraxane in Treatment of Metastatic Breast Cancer

作　　者：洪熠[1] 陈心华[1] 李娜妮[1] 林琳[1] 李重颖[1] 刘健[1] 

机构地区：[1]福建省肿瘤医院乳腺内科,福州市350014

出　　处：《中国肿瘤临床》2012年第6期352-354,共3页Chinese Journal of Clinical Oncology

摘　　要：目的:观察并比较注射用白蛋白结合型紫杉醇与普通紫杉醇治疗转移性乳腺癌的近期疗效及安全性。方法:将75例晚期转移乳腺癌患者随机分为2组,试验组37例患者接受注射用白蛋白结合型紫杉醇单药治疗,对照组38例接受普通注射用紫杉醇单药治疗,观察2组患者的近期疗效和不良反应。结果:试验组白蛋白结合型紫杉醇:完全缓解1例,部分缓解15例,稳定14例,进展7例,总有效率(CR+PR)为48.65%;对照组普通紫杉醇完全缓解0例,部分缓解9例,稳定19例,进展10例,总有效率为23.68%。两组患者治疗后主要不良反应为骨髓抑制及周围神经毒性。结论:白蛋白结合型紫杉醇治疗复发转移性乳腺癌疗效较好,不艮反应可以耐受。Objective： This work aims to observe the short-term efficacy of Abraxane in treating patients with metastatic breast cancer. Methods： A total of 75 patients with advanced and metastatic breast cancer were randomized into two groups. Group One （ test group ） comprised 37 patients who were treated with Abraxane monotherapy. Group Two （ control group ） comprised 38 patients who were treated with conventional injection of single-agent paclitaxel medication. The two groups were observed for short-term efficacy and adverse events. Results： In Group One, complete remission （ CR ） was found in 1 patient, partial remission （ PR ） in 15, stable dis- ease （ SD ） in 14, and progression of disease （ PD ） in 7. In Group Two, CR was not observed, PR in 9, SD in 19, and PD in 10 patients. The total remission rates in Groups One and Two were 43.24% and 23.68%, respectively. The most commonly observed adverse events in the two groups were myelo-supression and neurotoxicity. Conclusion： Abraxane treatment of metastatic breast cancer has a favorable therapeutic efficacy, and the adverse reactions are tolerable.

关 键 词：白蛋白结合型紫杉醇 紫杉醇 转移性乳腺癌 化疗 

分 类 号：R737.9[医药卫生—肿瘤]